Key result
Lidocaine reduces infarct size ~27% versus untreated controls in a canine ischemia-reperfusion model.
Why the study?
Does lidocaine reduce infarct size in a canine model of ischemia and reperfusion?
Population
20 dogs undergoing a 90-min left anterior descending artery ligation and 300 min of reperfusion
Comparison
Lidocaine infused 90 min prior to and during… vs Untreated
Design
Preclinical
Follow-up
300 min of reperfusion
Authors
Loading...
Lidocaine may merit human safety trials in reperfusion; leaves open translation from canine infarct models to clinical practice.
Does lidocaine reduce infarct size in a canine model of ischemia and reperfusion?
Absolute Event Rate: 35.2% vs 48.5%
p-value: p=<0.05
Lidocaine infusion prior to and during ischemia and reperfusion reduces myocardial infarct size in a canine model, potentially by protecting the myocardial cell membrane from lipid peroxidation.
Lesnefsky et al. (1989) studied Myocardial ischemia and reperfusion (n=20). Lidocaine vs. Untreated was evaluated on Ratio of infarct to risk area (p=<0.05). Lidocaine infusion reduced the ratio of infarct to risk area compared to untreated controls (35.2% vs 48.5%; p<0.05) in a canine model of ischemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: